SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN ...
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's ...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol ...
Amneal Pharmaceuticals (AMRX) announced the FDA has approved the company’s iohexol injection, the first generic version of GE Healthcare’s Omnipaque injection. Amneal expects to launch the product in ...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results